Product Brochures - Neurology
therapeutic advances in neurological disorders | December 18, 2019
Milà-Alomà M, Suárez-Calvet M and Molinuevo JL. Therapeutic Advances in Neurological Disorders. 2019;12:1756286419888819. doi: https://doi.org/10.1177/1756286419888819 ABSTRACT
June 04, 2019
Quanterix is re-engineering ultrasensitivity with the launch of the Simoa HD-X Analyzer™, the latest model fully automated Simoa bead-based immunoassay platform.
Simoa assays can detect biomarkers associated with brain injury and disease at much earlier stages to understand the long term effects and disease pathology.
Blood Will Tell
The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, will transform the way brain injuries and diseases are diagnosed. Learn more about how the Simoa Platform can advance your CNS biomarker detection!